Fcγ-receptors (FcγR) provide a critical link between humoral and cellular immunity. The genes of the low-affinity receptors for IgG and their isoforms, namely, FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIIb, and SH-FcγRIIIb, are located in close proximity on chromosome 1q22. Variant alleles may differ in biologic activity and a number of studies have reported the frequencies of variant FcγR alleles in both disease and control populations. No large study has evaluated the possibility of a nonrandom distribution of variant genotypes. We analyzed 395 normal individuals (172 African Americans [AA] and 223 Caucasians [CA]) at the following loci: FcγRIIa, FcγRIIIa, and FcγRIIIb, including the SH-FcγRIIIb. The genotypic distributions of FcγRIIa, FcγRIIIa, and FcγRIIIb conform to the Hardy-Weinberg law in each group. There was no strong evidence that combinations of 2-locus genotypes of the 3 loci deviated from random distributions in these healthy control populations. The distribution of SH-FcγRIIIb is underrepresented in CA compared with AA (P < .0001) controls. A previously reported variant FcγRIIb was not detected in 70 normal individuals, indicating that this allele, if it exists, is very rare (<1%). In conclusion, we present data that should serve as the foundation for the interpretation of association studies involving multiple variant alleles of the low-affinity FcγR.

RECEPTORS FOR THE Fc domain of IgG (FcγR) are mainly expressed on cells of hematopoietic lineage and provide a critical link between humoral and cellular immunity.1,2 These receptors mediate a variety of biological responses, including antibody-dependent cellular cytotoxicity, endocytosis, phagocytosis, release of inflammatory mediators, and augmentation of antigen presentation.1,3FcγR are divided into 3 classes: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). Within each class, isoforms have been identified that vary in molecular weight, in binding affinity to different subclasses of human IgG, and in distribution on the surface of hematopoietic cells. A further level of complexity is introduced by the presence of variant alleles in the low-affinity receptors: FcγRIIa, IIb, IIIa, and IIIb. In some cases, variant forms of the low-affinity receptors have been reported to have biologic differences in in vitro assays. A burgeoning number of association studies, correlating clinical outcomes with variant alleles, underscores the potential importance of these variant alleles in vivo. Accordingly, it is critical to determine the distribution of variant genotypes individually and in combination in a large control population to interpret association studies that seek to evaluate multiple FcγR genotypes in combination.

The structural heterogeneity and complex nature of the isoforms and their variant alleles reflect the functional diversity mediated by these receptors. The low-affinity receptors (FcγRIIa, IIb, IIIa, and IIIb) colocalize with other genes of hematopoietic and immunologic interest to a region in chromosome 1q22 that includes the receptor for interleukin-6, C-reactive protein, the selectin cluster, and the Duffy blood group.4-8 It is estimated that the maximum distance between any of the 2 low-affinity FcγR genes (FcγRIIa, IIb, IIIa and IIIb) is approximately 200 kb.4,9 The location of a recently described variant, SH-FcγRIIIb, which has been identified in individuals in whom a polymerase chain reaction (PCR) fragment can be amplified with NA2-specific primers derived from FcγRIIIb, is not known at this time.10,11 

Preliminary results of the human genome project suggest that polymorphisms occur approximately once every 800 to 1,200 bp.12 In regions sharing a high degree of homology, such as the FcγR, crossing over may be favored, and one might expect to see a greater frequency of recombination events and, perhaps, polymorphisms.13 However, only a handful of biologically or clinically significant variant alleles of the low-affinity FcγR, FcγRIIa, IIb, IIIa, and IIIb have been identified.

It has been reported that some variant alleles of the low-affinity FcγR are of functional or clinical importance. For example, FcγRIIa has 2 codominantly expressed alleles that differ at 1 amino acid, R131 and H131.14 These were initially identified on the basis of a functional polymorphism related to murine IgG1 binding and were designated as low responder (LR) and high responder (HR), respectively.15,16 Several groups have shown a decreased ability of the R131 allele to bind human IgG2.14,17-20 Both FcγRIIIa, which is expressed on NK cells and phagocytic cells, and FcγRIIIb, which is expressed on neutrophils, display codominant biallelic variants.21-24 The 158F allele of FcγRIIIa has been shown to bind IgG1, IgG3, and IgG4 less avidly.23,24We limited our analysis of the FcγRIIIa gene to the V and F alleles at amino acid 158 and did not analyze the tri-allelic polymorphism, 48 L/H/R, which is probably linked to 158 V/F and also appears not to confer a significant biologic difference.23,25 The 2 allotypes of FcγRIIIb, assigned as neutrophil antigen (NA) 1 and 2, differ in at least 5 nucleotides, resulting in changes of 4 amino acids in the membrane-distant Ig-like domain.21,22 In comparison to the neutrophils obtained from NA1 homozygous donors, neutrophils from NA2 homozygous individuals bind human IgG3 less effectively and were consistently found to exhibit lower levels of phagocytosis of erythrocytes sensitized with IgG1 and IgG3 anti-Rhesus D monoclonal antibody.26-28 Furthermore, phagocytosis of IgG1-opsonized bacteria by FcγRIIIb-NA2 neutrophils was also reduced in comparison to FcγRIIIb-NA1 neutrophils, whereas no difference was found using IgG2-opsonized bacteria.28 A single nucleotide change at nucleotide 885 in FcγRIIb1 (T → G) has been reported at the cDNA level only.29 The proposed change of 1 amino acid appears to alter receptor internalization and capping in in vitro studies.29,30 In addition, we investigated the distribution of the recently described SH-FcγRIIIb, which differs from the wild-type NA-2 allele by at least 1 single nucleotide, although a biologic difference has not been established.10,11 

The purpose of our study was to determine the frequency of selected variant alleles of the low-affinity FcγR genes in a large, healthy control population. To this end, we genotyped 395 normal healthy individuals (172 African Americans [AA] and 223 Caucasians [CA]) and determined the distribution and frequency of biologically important variant alleles of FcγRIIa, IIb, IIIa, and IIIb, including SH-FcγRIIIb. We have sought to identify whether there is nonrandom distribution of combinations of variant genotypes in these 2 populations. Understanding the distribution of multiple FcγR variant genotypes in control populations furnishes a critical foundation upon which to interpret future association studies. Our study provides a basis upon which the independent segregation of individual FcγR genes within a population may be estimated. Understanding the extent of the interaction between multiple FcγR genotypes could lead to further insight into the contribution of this complex family of genes to various pathologic conditions.31-33 

Subjects

Genomic DNA was isolated from peripheral blood using either a phenol-chloroform extraction method (5 Prime-3 Prime, Inc, Boulder, CO) or Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN). Blood samples from 395 normal healthy individuals, consisting of 172 AA and 223 CA, were available for genomic DNA extraction under an Institutional Review Board-approved protocol for anonymous genomic DNA collection under the supervision of the Department of Transfusion Medicine, Clinical Center, National Institutes of Health (Bethesda, MD). Only the race and sex were recorded and linked to an anonymous identifier during collection of samples.

Determination of the Polymorphic Forms of the Low-Affinity FcγR

Genomic DNA was amplified according to conditions specific for each FcγR. Genotype analysis was completed before statistical analysis. All assays were performed at least twice.

FcγRIIa.

The previously reported polymorphism in the coding region of FcγRIIa was determined by allele-specific restriction digest according to methods described by Jiang et al.34 A mutant oligonucleotide-directed restriction site was created in the 5′ end of the amplicon using the following sense primer: GGAAAATCCCAGAAATTCTCGC. The less frequent, variant allele, R, contains a BstUI restriction digest site (an introduced G compared with the wild-type A). The antisense primer, CAACAGCCTGACTACCTATTACGCGGG, corresponding to a sequence in the next intron, assures gene specific amplification and introduces a second BstUI restriction site that serves as an internal control for restriction digestion. PCR amplification was performed in a 50 μL reaction with 50 ng genomic DNA, 100 ng of each primer, 200 μmol/L each dNTP, 0.5 U Taq DNA polymerase (Boehringer Mannheim, Mannheim, Germany), and the manufacturer's buffer. A denaturation step of 95°C for 5 minutes was followed by 30 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 40 seconds. After BstUI digestion, samples were analyzed on a 3% agarose gel.

FcγRIIb.

Direct sequence analysis was performed on amplicons amplified using the following sense and antisense primers, TCCCATCCAACCCTGGA and GGCAGATTCCTCAGCAAATCA, respectively. Fifty-microliter reactions containing 50 ng genomic DNA, 150 ng of each primer, 200 μmol/L dNTP, and 0.5 U Taq polymerase were amplified under the following conditions: initial denaturation at 95°C for 5 minutes, followed by 30 cycles of 95°C for 30 seconds, 56°C for 30 seconds, and 72°C for 60 seconds. The primers used for amplification were used for sequencing with the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham Life Sciences, Inc, Cleveland, OH) at 35 cycles and an annealing temperature of 55°C.

FcγRIIIa.

The 158V/F-FcγRIIIa polymorphism was discriminated by an allele-specific oligohybridization of a nested PCR amplification of genomic DNA. A gene-specific, 1.2-kb fragment was amplified using the following sense and antisense primers, ATATTTACAGAATGGCACAGG and GACTTGGTACCCAGGTTGAA, respectively, in a 25 μL reaction with 20 ng of genomic DNA, 75 ng of each primer, 200 μmol/L dNTP, and 0.25 U Taq polymerase. PCR conditions were as follows: 5 minutes of initiation denaturation at 95°C, followed by 35 cycles at 95°C for 1 minute, 56°C for 1 minute, and 72°C for 1 minute. One microliter of this reaction was transferred to a separate microfuge tube for nested PCR in a total volume of 50 μL that included 150 ng of sense and antisense primers, TCATCATAATTCTGACTTCT and CTTGAGTGATGGTGATGTTC, 200 μmol/L dNTP, and 0.5 U Taq polymerase. PCR conditions for the second amplification consisted of 30 cycles of 95°C for 1 minute, 62°C for 1 minute, and 72°C for 1 minute. Ten microliters of the final PCR reaction was transferred to a nylon filter in duplicate (Hybond N+; Amersham). Each filter was hybridized with a [γ-32P]-ATP-labeled oligonucleotide probe corresponding to the F or V allele, GCAGGGGGCTTTTTGGGAGTAAA or GCAGGGGGCTTGTTGGGAGTAAA. The blots were washed in 6× SSPE with 1% sodium dodecyl sulfate (SDS) at room temperature, 42°C, and twice for 10 minutes each time at 70.5°C for the probe containing the T allele and at 72.5°C for the G allele. Autoradiography was performed and analyzed between 8 and 24 hours later.

FcγRIIIb.

Polymorphic forms of FcγRIIIb were determined by gene- and allele-specific PCR with the following primer pairs, NA1-sense, CTCAATGGTACAGGGTGCTC and NA1-antisense, GGCCTGGCTTGAGATGAGGT or NA2-sense, CTCAATGGTACAGCGTGCTT and NA2-antisense, CACCTGTACTCTCCACTGTCGTT, using a modified protocol according to Hessner et al.35 Control amplification of a 383-bp segment of the C-myc gene was included in each tube with the following primer pair, ACGCCCCTCAACGTTAGCTT and CGCAGATGAAACTCTGGTTCACCAT. Fifty nanograms of genomic DNA was amplified in 50 μL reaction containing 200 μmol/L dNTP, 10 ng of each Myc-primer, 0.5 U Taq polymerase, and either primer pair for NA1 or NA2. The PCR conditions were as follows: 30 cycles of 94°C for 1 minute, 67°C for 1 minute, and 72°C for 1 minute. PCR products were visualized on a 3% agarose gel.

SH-FcγRIIIb.

The reported sequence variation observed in individuals in whom an amplicon can be amplified with NA2-specific primers, SH-FcγRIIIb, was determined by allele-specific digest of a PCR amplicon withSfaNI as described by Bux et al.10 Using the allele-specific primer pair for FcγRIIIb-NA2 under conditions detailed above, digestion with the restriction endonucleaseSfaNI was performed for 3 hours and the products were visualized on a 3% agarose gel.

Literature Search

Citations including information on variant alleles of the FcγR and associated clinical studies were identified by performing searches using PubMed extending back to 1980 (National Center for Biotechnology and Information, National Library of Medicine, National Institutes of Health). Keywords included polymorphism, allele, Fc receptor, FcγReceptor, and clinical association. Additional references were identified from bibliographies of identified references.

Statistical Analysis

Allele frequencies were computed from the observed data and deviations of observed genotypic distributions from expected distributions based on the Hardy-Weinberg law were tested using a χ2 test statistic with 1 degree of freedom. For comparison of 2-locus genotypic distributions from random expectations, a χ2 test with 4 degrees of freedom was performed on each 3 × 3 table of genotypes. In this exploratory analysis, P values were corrected by a factor of 3, which correlates with the number of loci examined. For any 2-locus test with a P value less than .05, we looked at specific combinations of genotypes by making 3 × 2 tables and computing a χ2 test with 2 degrees of freedom. Similarly, these P values were corrected by a factor of 3 on the premise that the analysis looked at 3 different genotypes. Statistical analysis was performed using the Macintosh 2.0 version of InStatR (GraphPad Software, San Diego, CA).

A total of 395 individuals (172 AA and 223 CA) were genotyped for at least 1 low-affinity receptor, FcγRIIa, FcγRIIIa, or FcγRIIIb (Table 1). For each of the FcγR examined, the genotypic distributions in both populations analyzed conform to the Hardy-Weinberg equilibrium (Table 2). In 5 individuals (1.3%), no FcγRIIIb gene was detectable, in accordance with previously reported data indicating that less than 1% of the population lacks the FcγRIIIb phenotype or that additional polymorphisms interfere with allele-specific amplification.36 The allelic frequencies of FcγRIIa, and FcγRIIIb did not differ between AA and CA, but in the FcγRIIIa, there was a marginal difference between the 2 groups for the heterozygotes 158V/F (P = .048).

Table 1.

Genotype Distribution of FcγRIIa, FcγRIIIa, and FcγRIIIb in Normal, Healthy Controls

FcγRIIaFcγRIIIa FcγRIIIb
HH HRRR FF VF*VV NA1NA1 NA1NA2 NA2NA2
AA 44 (26%)  73 (43%)  53 (31%)  64 (42%) 76 (50%)  12 (8%)   27 (16%)   82 (49%) 60 (35%)  
CA  69 (31%)  97 (44%)  54 (25%) 91 (50%)  71 (39%)* 19 (11%)  21 (10%) 103 (47%)  93 (43%) 
FcγRIIaFcγRIIIa FcγRIIIb
HH HRRR FF VF*VV NA1NA1 NA1NA2 NA2NA2
AA 44 (26%)  73 (43%)  53 (31%)  64 (42%) 76 (50%)  12 (8%)   27 (16%)   82 (49%) 60 (35%)  
CA  69 (31%)  97 (44%)  54 (25%) 91 (50%)  71 (39%)* 19 (11%)  21 (10%) 103 (47%)  93 (43%) 

All P values are >.05 unless otherwise indicated. Five individuals (2 AA and 3 CA) were lacking the FcγRIIIb gene (1.27%).

*

P = .048.

Table 2.

Single Locus Test for Hardy-Weinberg Equilibrium of Low-Affinity Fcγ Receptors: FcγRIIa, FcγRIIIa, and FcγRIIIb

AA
FcγRIIa FcγRIIIaFcγRIIIb
Allele H = 0.47  Allele V = 0.33  Allele 1 = 0.4  
Allele R = 0.53  Allele F = 0.67  Allele 2 = 0.6  
Expected H/R = 0.50  Expected V/F = 0.44 Expected 1/2 = 0.48  
Observed H/R = 0.43  Observed V/F = 0.50  Observed 1/2 = 0.49  
χ2 = 3.31 χ2 = 2.65  χ2 = .02 
P = .07  P = .10  P > .10 
CA  
FcγRIIa  FcγRIIIa  FcγRIIIb  
Allele H = 0.53  Allele V = 0.30  Allele 1 = 0.33  
Allele R = 0.47  Allele F = 0.70  Allele 2 = 0.67  
Expected H/R = 0.50  Expected V/F = 0.42  Expected 1/2 = 0.44  
Observed H/R = 0.44 Observed V/F = 0.39  Observed 1/2 = 0.47 
χ2 = 2.89  χ2 = .85 χ2 = 1.01  
P = .09 P > .10  P > .10 
AA
FcγRIIa FcγRIIIaFcγRIIIb
Allele H = 0.47  Allele V = 0.33  Allele 1 = 0.4  
Allele R = 0.53  Allele F = 0.67  Allele 2 = 0.6  
Expected H/R = 0.50  Expected V/F = 0.44 Expected 1/2 = 0.48  
Observed H/R = 0.43  Observed V/F = 0.50  Observed 1/2 = 0.49  
χ2 = 3.31 χ2 = 2.65  χ2 = .02 
P = .07  P = .10  P > .10 
CA  
FcγRIIa  FcγRIIIa  FcγRIIIb  
Allele H = 0.53  Allele V = 0.30  Allele 1 = 0.33  
Allele R = 0.47  Allele F = 0.70  Allele 2 = 0.67  
Expected H/R = 0.50  Expected V/F = 0.42  Expected 1/2 = 0.44  
Observed H/R = 0.44 Observed V/F = 0.39  Observed 1/2 = 0.47 
χ2 = 2.89  χ2 = .85 χ2 = 1.01  
P = .09 P > .10  P > .10 

Allele frequencies and the expected and observed frequency of heterozygotes are presented. Data were analyzed using χ2test for heterogeneity with 1 degree of freedom.

To further investigate the possibility of a nonrandom distribution of genotypes in a healthy population, we concentrated our analysis on 330 individuals (150 AA and 180 CA) who were successfully typed at the 3 loci for FcγRIIa, FcγRIIIa, and FcγRIIIb. The distribution of allelic variations in this subgroup did not differ significantly from the distribution observed in the total group (data not shown). There was no strong evidence for nonrandom distribution of combinations of variant genotypes in either population (Table 3). It should be noted that, in the CA population, there is a marginally significant P value for the combination of FcγRIIIa and FcγIIIb (P = .046), suggesting an overrepresentation of 1 or more combinations of variant genotypes. When we analyzed this group individually, the only notable finding was for the combination of the 158F/F genotype of FcγRIIIa and the FcγRIIIb alleles (P = .016 corrected for multiple comparisons; n = 3). The other genotypes, V/F and V/V of 158, did not demonstrate a skewed distribution of combinations of the variant genotypes of the 2 loci.

Table 3.

Analysis of Variant Genotypes of FcγRIIa, FcγRIIIa, and FcγRIIIb in a Healthy, Control Population

AA CA
FcγRIIa FcγRIIIa  FcγRIIa FcγRIIIa  
HH  FF  16 (40%) HH  FF  21 (37%)  
HH  VF  18 (45%)  HH  VF 24 (43%)  
HH  VV  6 (15%)  HH  VV  11 (20%) 
HR  FF  24 (38%)  HR  FF  42 (52%)  
HR  VF 35 (54%)  HR  VF  32 (39%)  
HR  VV  5 (8%) HR  VV  7 (9%)  
RR  FF  23 (50%)  RR  FF 27 (63%)  
RR  VF  22 (48%)  RR  VF 15 (35%)  
RR  VV  1 (2%)  RR  VV  1 (2%) 
χ2 = 5.97 P = NS  χ2 = 11.02 P = .078  
FcγRIIa FcγRIIIb  FcγRIIa FcγRIIIb  
HH  NA1NA1 13 (32%)  HH  NA1NA1  9 (16%)  
HH  NA1NA2 15 (38%)  HH  NA1NA2  29 (55%)  
HH  NA2NA2 12 (30%)  HH  NA2NA2  16 (29%)  
HR  NA1NA1 9 (14%)  HR  NA1NA1  8 (10%)  
HR  NA1NA2 27 (42%)  HR  NA1NA2  41 (50%)  
HR  NA2NA2 28 (44%)  HR  NA2NA2  32 (40%)  
RR  NA1NA1 3 (7%)  RR  NA1NA1  3 (7%)  
RR  NA1NA2 25 (57%)  RR  NA1NA2  15 (35%)  
RR  NA2NA2 16 (36%)  RR  NA2NA2  24 (58%) 
χ2 = 11.94 P = .053  χ2 = 8.41 P = NS  
FcγRIIIa FcγRIIIb  FcγRIIIa FcγRIIIb  
FF  NA1NA1 13 (21%)  FF  NA1NA1  15 (17%)  
FF  NA1NA2 26 (42%)  FF  NA1NA2  47 (53%)  
FF  NA2NA2 23 (37%)  FF  NA2NA2  27 (30%)  
VF  NA1NA1 10 (14%)  VF  NA1NA1  3 (4%)  
VF  NA1NA2 34 (47%)  VF  NA1NA2  33 (46%)  
VF  NA2NA2 30 (39%)  VF  NA2NA2  35 (50%)  
VV  NA1NA1 2 (17%)  VV  NA1NA1  2 (11%)  
VV  NA1NA2 7 (58%)  VV  NA1NA2  5 (28%)  
VV  NA2NA2 3 (25%)  VV  NA2NA2  10 (61%) 
χ2 = 2.39 P = NS  χ2 = 12.27 P = .046  
AA CA
FcγRIIa FcγRIIIa  FcγRIIa FcγRIIIa  
HH  FF  16 (40%) HH  FF  21 (37%)  
HH  VF  18 (45%)  HH  VF 24 (43%)  
HH  VV  6 (15%)  HH  VV  11 (20%) 
HR  FF  24 (38%)  HR  FF  42 (52%)  
HR  VF 35 (54%)  HR  VF  32 (39%)  
HR  VV  5 (8%) HR  VV  7 (9%)  
RR  FF  23 (50%)  RR  FF 27 (63%)  
RR  VF  22 (48%)  RR  VF 15 (35%)  
RR  VV  1 (2%)  RR  VV  1 (2%) 
χ2 = 5.97 P = NS  χ2 = 11.02 P = .078  
FcγRIIa FcγRIIIb  FcγRIIa FcγRIIIb  
HH  NA1NA1 13 (32%)  HH  NA1NA1  9 (16%)  
HH  NA1NA2 15 (38%)  HH  NA1NA2  29 (55%)  
HH  NA2NA2 12 (30%)  HH  NA2NA2  16 (29%)  
HR  NA1NA1 9 (14%)  HR  NA1NA1  8 (10%)  
HR  NA1NA2 27 (42%)  HR  NA1NA2  41 (50%)  
HR  NA2NA2 28 (44%)  HR  NA2NA2  32 (40%)  
RR  NA1NA1 3 (7%)  RR  NA1NA1  3 (7%)  
RR  NA1NA2 25 (57%)  RR  NA1NA2  15 (35%)  
RR  NA2NA2 16 (36%)  RR  NA2NA2  24 (58%) 
χ2 = 11.94 P = .053  χ2 = 8.41 P = NS  
FcγRIIIa FcγRIIIb  FcγRIIIa FcγRIIIb  
FF  NA1NA1 13 (21%)  FF  NA1NA1  15 (17%)  
FF  NA1NA2 26 (42%)  FF  NA1NA2  47 (53%)  
FF  NA2NA2 23 (37%)  FF  NA2NA2  27 (30%)  
VF  NA1NA1 10 (14%)  VF  NA1NA1  3 (4%)  
VF  NA1NA2 34 (47%)  VF  NA1NA2  33 (46%)  
VF  NA2NA2 30 (39%)  VF  NA2NA2  35 (50%)  
VV  NA1NA1 2 (17%)  VV  NA1NA1  2 (11%)  
VV  NA1NA2 7 (58%)  VV  NA1NA2  5 (28%)  
VV  NA2NA2 3 (25%)  VV  NA2NA2  10 (61%) 
χ2 = 2.39 P = NS  χ2 = 12.27 P = .046  

A 3 × 3 χ2 test with 4 degrees of freedom was performed for each 2-locus comparison (ie, HH, HR, RR and VV, VF, FF).P values are corrected by a factor of 3, reflecting the exploratory comparison of 3 separate loci. Individuals lacking the FcγRIIIb gene are not included.

Abbreviation: NS, not significant.

Of the 330 individuals genotyped for both FcγRIIIb and SH-FcγRIIIb, the variant sequence of SH-FcγRIIIb was observed exclusively in individuals in whom a PCR fragment could be amplified with NA2-specific primers (Table 4). Accordingly, no individuals homozygous for NA1 had evidence of the sequence of SH-FcγRIIIb. The A sequence, which denotes SH-FcγRIIIb, was significantly underrepresented in CA compared with AA (P < .0001; Table 4).37 We further analyzed the distribution of the SH-FcγRIIIb genotype in individuals in whom a PCR product could be amplified with NA2 specific primers (Table 5). In the AA population, which has a higher frequency of detecting the variant SH-FcγRIIIb sequence, there was no difference in the distribution between those individuals with only NA2 primer-generated products (ie, no NA1 product was seen separately) and those individuals who also had an NA1 allele. These results suggest that SH-FcγRIIIb in AA appears to be randomly distributed between the 2 genotypes that contain fragments generated with NA2-specific primers (ie, with and without the presence of NA1). For those individuals in whom an amplicon was amplified with NA2 primers and complete SfaN1 digestion was observed, it is assumed that only the SH-FcγRIIIb sequence is present. From our typing assays, it is not possible to conclude whether 1 or 2 copies of the SH-FcγRIIIb sequence are present; an FcγRIIIb null gene could be present. Furthermore, our results indicate that, in some individuals, there might be duplication or redundancy of the FcγRIIIb gene, because SH-FcγRIIIb (as indicated by heterozygosity with respect to SfaN1 digestion) is detected in individuals with the NA1 allele and a fragment amplified with the NA2-specific primers (Table 5). Of the 43 AA who were positive for SH-FcγRIIIb, in 29, incomplete Sfa1 digestion was observed (67% of SH-FcγRIIIb and 24% of the total population), indicating either duplication or redundancy of the FcγRIIIb gene, whereas in 14 AA individuals (33% of SH-FcγRIIIb positive and 11% overall), only the SH-FcγRIIIb sequence was detected. In only 1 of 8 CA patients who were positive for SH-FcγRIIIb, complete SfaN1 digestion was observed.

Table 4.

Genotype Distribution of SH-FcγRIIIb in Individuals in Whom a PCR Fragment Could Be Amplified With NA2-Specific Primers

AA (n = 123) CA (n = 157)
SH(−) 80 (65%)  149 (95%)  
SH(+)  43 (35%)  8 (5%)  
 P < .0001  
AA (n = 123) CA (n = 157)
SH(−) 80 (65%)  149 (95%)  
SH(+)  43 (35%)  8 (5%)  
 P < .0001  

Individuals in this analysis were restricted to those in whom a PCR fragment was amplified with NA2-specific primers (84% of AA and 90% of CA). SfaN1 digestion of amplicon generated with NA2-specific oligonucleotide primers was analyzed by agarose gel; digestion by SfaN1 indicates the presence of the SH-FcγRIIIb sequence. The difference between the 2 groups was significant at P < .0001.

Table 5.

Distribution of Variant Genotypes of SH-FcγRIIIb in Individuals, as Determined by SfaN1 Digestion of PCR Fragments Amplified With NA2-Specific Primers

AA CA
Positive Amplification With Primers Corresponding to Pattern of SfaN1 Digestion Positive Amplification With Primers Corresponding to Pattern of SfaN1 Digestion
NA1 + NA2  CC  44 (66%)  NA1 + NA2  CC 80 (94%)  
 AC  14 (21%)   AC  4 (5%) 
 AA  9 (13%)   AA  1 (1%)  
NA2 only  CC 36 (64%)  NA2 only  CC  69 (96%)  
 AC 15 (26%)   AC  3 (4%)  
 AA 5 (9%)   AA  0 (0%) 
χ2 = 1.0 P = .60  χ2 = .88 P = .64  
AA CA
Positive Amplification With Primers Corresponding to Pattern of SfaN1 Digestion Positive Amplification With Primers Corresponding to Pattern of SfaN1 Digestion
NA1 + NA2  CC  44 (66%)  NA1 + NA2  CC 80 (94%)  
 AC  14 (21%)   AC  4 (5%) 
 AA  9 (13%)   AA  1 (1%)  
NA2 only  CC 36 (64%)  NA2 only  CC  69 (96%)  
 AC 15 (26%)   AC  3 (4%)  
 AA 5 (9%)   AA  0 (0%) 
χ2 = 1.0 P = .60  χ2 = .88 P = .64  

SfaN1 digestion of amplicon generated with NA2-specific oligonucleotide primers was analyzed by agarose gel; SH-FcγRIIIb can only be detected in individuals in whom a product can be amplified with NA2-specific primers. Digestion by SfaN1 indicates the presence of the SH-FcγRIIIb sequence. Specifically, a nucleotide change at position 266 from C to A results in a change of alanine to aspartic acid at residue 78. Data were analyzed using a 3 × 2 χ2test for heterogeneity with 2 degrees of freedom. Sequence difference at nucleotide position 266: C, reported NA2 sequence; A, SH-FcγRIIIb.

A variant cDNA has been isolated corresponding to a possible polymorphism in FcγRIIb that alters its biologic function.29,30 We directly sequenced 140 separate chromosomes from 52 CA and 18 AA individuals and in each case identified T at bp 885 and no G. We conclude that this proposed variant of FcγRIIb is very rare, if it exists.

A comparison of our results with those of published studies, identified using PubMed, which generally report on only 1 FcγR variant allele, is shown in a meta-analysis in Table 6. The largest collection of studies has been reported for the H/R genotypes of FcγRIIa. In total, 2,419 CA have been genotyped and reported in 23 studies including 24 separate populations.32,38-57,61,66 An analysis of the distribution of variant genotypes of FcγRIIa was performed between individual study populations and the remaining published population as well as against the population reported here. In 3 of the 23 studies, there was a difference detected by 3 × 2 χ2 analysis.32,38,39 Interestingly, these included the 2 largest studies and 1 of the smallest studies. Comparison of our study results to the total in Table 6 did not show a significant difference overall (P = .14; χ2 = 3.99) or by genotype (data not shown). Similarly, there was no difference between the reported populations of AA at the FcγRIIa locus or between our population and the total of the 3 studies.38,54,58 However, there is an appreciable difference in the distribution of variant FcγRIIa genotypes in populations from the Far East.31,38,56,60 

Table 6.

Published Data of Frequencies of Variant Genotypes of the Low-Affinity Fcγ Receptors

FcγRIIa Population No. HH HR RRComparison With Other Populations6-150Reference
CA     (P)  
 UK  259  57 (22%) 120 (46%)  82 (32%)  (.0067)  Botto38 
 Germany  256  71 (28%)  134 (52%)  51 (20%)  Carlsson66 
 France  218  75 (34%) 99 (45%)  44 (21%)  (.0093) Bachelot-Loza39 
 Germany  187  53 (28%) 84 (45%)  50 (27%)   Manger40 
 United States  149  38 (26%)  79 (53%)  32 (21%)  Edberg41 
 Netherlands  123  36 (29%) 59 (48%)  28 (23%)   Sanders42 
 Russia  107  30 (28%)  58 (54%)  19 (18%)  Platonov43 
 United States6-151 102 20 (20%)  56 (55%)  26 (25%)  Arepally44 
 United States  100 19 (19%)  49 (49%)  32 (32%)  Brandt45 
 Canada  100  26 (26%) 52 (52%)  22 (22%)   Horsewood46 
 Canada  95  20 (21%)  49 (52%)  26 (27%)  Denomme47 
 Finland  93  25 (27%) 55 (59%)  13 (14%)   Joutsi48 
 Netherlands  87  24 (28%)  44 (50%)  19 (22%)  Koene61 
 Netherlands  69  22 (32%) 36 (52%)  11 (16%)   Duits49 
 UK 66  12 (18%)  38 (58%)  16 (24%)  Smyth50 
 Ireland  61  15 (25%) 35 (57%)  11 (18%)   Williams51 
 United States6-152 56  11 (20%)  26 (46%) 19 (34%)   Abadi52 
 United States6-152 56  11 (20%)  30 (54%)  15 (27%)  Salmon53 
 Greece  52  20 (39%) 24 (46%)  8 (15%)   Smyth50 
 Norway 49  9 (18%)  18 (37%)  22 (45%)  (.0023) Raknes32 
 United States  47  14 (30%) 24 (51%)  9 (19%)   Reilly54 
 UK 40  9 (23%)  22 (55%)  9 (23%)   Caliz (a)55 
 United States  35  8 (23%) 19 (54%)  8 (23%)   Osborne56 
 Australia  22  2 (9%)  13 (60%)  7 (31%)  Burgess57 
 
Total  2419  627 (26%) 1,223 (50%)  579 (24%) 
6-1532 = 3.99, P = .14v CA of Table 1)
 
FcγRIIa Population  No. HH  HR  RR   Reference  
AA  
 United States 100  27 (27%)  50 (50%)  23 (23%)  Salmon58 
 Caribbean  77  17 (22%) 35 (45%)  25 (33%)   Botto38 
 United States  50  7 (14%)  30 (60%)  13 (26%)  Reilly54 
      Norris59 
 
Total  227 51 (22%)  115 (51%)  61 (27%) 
6-1532 = 2.32, P = .31v AA of Table 1)
 
FcγRIIa Population  No.  HH  HR  RR   Reference  
Far East 
 Japan  105  63 (60%)  38 (36%)  4 (4%)  Kobayashi31 
 Korea  64  22 (34%) 37 (58%)  5 (8%)   Song60 
 China 49  24 (49%)  20 (41%)  5 (10%)  Botto38 
 China  18  9 (50%) 8 (44%)  1 (6%)   Osborne56 
 Japan 18  11 (61%)  6 (33%)  1 (6%)  Osborne56 
 India  16  2 (13%) 9 (56%)  5 (31%)   Osborne56 
 
Total 270  131 (49%)  118 (43%)  21 (8%)   
FcγRIIIa Population  No.  FF  VF  VV  Reference  
CA  
 United States6-155 200 87 (43%)  92 (46%)  21 (11%)   Wu24 
 Netherlands  87  28 (32%)  44 (51%)  15 (17%)  Koene23 
 
Total  287  115 (40%) 136 (47%)  36 (13%) 
6-1532 = 4.69, P = .10v CA in Table 1)
 
FcγRIIa Population No. HH HR RRComparison With Other Populations6-150Reference
CA     (P)  
 UK  259  57 (22%) 120 (46%)  82 (32%)  (.0067)  Botto38 
 Germany  256  71 (28%)  134 (52%)  51 (20%)  Carlsson66 
 France  218  75 (34%) 99 (45%)  44 (21%)  (.0093) Bachelot-Loza39 
 Germany  187  53 (28%) 84 (45%)  50 (27%)   Manger40 
 United States  149  38 (26%)  79 (53%)  32 (21%)  Edberg41 
 Netherlands  123  36 (29%) 59 (48%)  28 (23%)   Sanders42 
 Russia  107  30 (28%)  58 (54%)  19 (18%)  Platonov43 
 United States6-151 102 20 (20%)  56 (55%)  26 (25%)  Arepally44 
 United States  100 19 (19%)  49 (49%)  32 (32%)  Brandt45 
 Canada  100  26 (26%) 52 (52%)  22 (22%)   Horsewood46 
 Canada  95  20 (21%)  49 (52%)  26 (27%)  Denomme47 
 Finland  93  25 (27%) 55 (59%)  13 (14%)   Joutsi48 
 Netherlands  87  24 (28%)  44 (50%)  19 (22%)  Koene61 
 Netherlands  69  22 (32%) 36 (52%)  11 (16%)   Duits49 
 UK 66  12 (18%)  38 (58%)  16 (24%)  Smyth50 
 Ireland  61  15 (25%) 35 (57%)  11 (18%)   Williams51 
 United States6-152 56  11 (20%)  26 (46%) 19 (34%)   Abadi52 
 United States6-152 56  11 (20%)  30 (54%)  15 (27%)  Salmon53 
 Greece  52  20 (39%) 24 (46%)  8 (15%)   Smyth50 
 Norway 49  9 (18%)  18 (37%)  22 (45%)  (.0023) Raknes32 
 United States  47  14 (30%) 24 (51%)  9 (19%)   Reilly54 
 UK 40  9 (23%)  22 (55%)  9 (23%)   Caliz (a)55 
 United States  35  8 (23%) 19 (54%)  8 (23%)   Osborne56 
 Australia  22  2 (9%)  13 (60%)  7 (31%)  Burgess57 
 
Total  2419  627 (26%) 1,223 (50%)  579 (24%) 
6-1532 = 3.99, P = .14v CA of Table 1)
 
FcγRIIa Population  No. HH  HR  RR   Reference  
AA  
 United States 100  27 (27%)  50 (50%)  23 (23%)  Salmon58 
 Caribbean  77  17 (22%) 35 (45%)  25 (33%)   Botto38 
 United States  50  7 (14%)  30 (60%)  13 (26%)  Reilly54 
      Norris59 
 
Total  227 51 (22%)  115 (51%)  61 (27%) 
6-1532 = 2.32, P = .31v AA of Table 1)
 
FcγRIIa Population  No.  HH  HR  RR   Reference  
Far East 
 Japan  105  63 (60%)  38 (36%)  4 (4%)  Kobayashi31 
 Korea  64  22 (34%) 37 (58%)  5 (8%)   Song60 
 China 49  24 (49%)  20 (41%)  5 (10%)  Botto38 
 China  18  9 (50%) 8 (44%)  1 (6%)   Osborne56 
 Japan 18  11 (61%)  6 (33%)  1 (6%)  Osborne56 
 India  16  2 (13%) 9 (56%)  5 (31%)   Osborne56 
 
Total 270  131 (49%)  118 (43%)  21 (8%)   
FcγRIIIa Population  No.  FF  VF  VV  Reference  
CA  
 United States6-155 200 87 (43%)  92 (46%)  21 (11%)   Wu24 
 Netherlands  87  28 (32%)  44 (51%)  15 (17%)  Koene23 
 
Total  287  115 (40%) 136 (47%)  36 (13%) 
6-1532 = 4.69, P = .10v CA in Table 1)
 
FcγRIIIb Population No. NA1NA1 NA1NA2 NA2NA2Reference
CA  
 United States6-152 99  17 (17%) 71 (72%)  11 (11%)   Hessner35 
 United States  90  10 (11%)  46 (51%)  34 (38%)  Hessner35 
 Netherlands  87  11 (12%) 39 (45%)  37 (43%)   Koene61 
 United States6-151 67  10 (15%)  30 (45%)  27 (40%)  Wainstein62 
 Norway  49  4 (8%) 28 (57%)  17 (35%)   Raknes32 
 
Total  392  52 (13%)  214 (55%)  126 (32%) 
6-153,6-1542 = 7.32, P = .026v CA in Table 1)
 
FcγRIIIb Population  No.  NA1NA1  NA1NA2  NA2NA2  Reference  
Far East  
 India  92  15 (16%) 26 (28%)  51 (55%)   Hessner35 
Native American  
 United States  98  20 (20%)  71 (71%) 9 (9%)   Hessner35 
6-153AA  
 United States 99  16 (16%)  30 (30%)  54 (54%)  Hessner35 
 
6-1532 = 10.25, P = .006v AA in Table 1)
 
FcγRIIIb Population No. NA1NA1 NA1NA2 NA2NA2Reference
CA  
 United States6-152 99  17 (17%) 71 (72%)  11 (11%)   Hessner35 
 United States  90  10 (11%)  46 (51%)  34 (38%)  Hessner35 
 Netherlands  87  11 (12%) 39 (45%)  37 (43%)   Koene61 
 United States6-151 67  10 (15%)  30 (45%)  27 (40%)  Wainstein62 
 Norway  49  4 (8%) 28 (57%)  17 (35%)   Raknes32 
 
Total  392  52 (13%)  214 (55%)  126 (32%) 
6-153,6-1542 = 7.32, P = .026v CA in Table 1)
 
FcγRIIIb Population  No.  NA1NA1  NA1NA2  NA2NA2  Reference  
Far East  
 India  92  15 (16%) 26 (28%)  51 (55%)   Hessner35 
Native American  
 United States  98  20 (20%)  71 (71%) 9 (9%)   Hessner35 
6-153AA  
 United States 99  16 (16%)  30 (30%)  54 (54%)  Hessner35 
 
6-1532 = 10.25, P = .006v AA in Table 1)
 
F6-150

The distribution of genotypes in each individual study was compared with the overall distribution of remaining published populations (including the population reported here) in a 3 × 2 χ2 analysis (with 2 degrees of freedom). Studies listed more than once report distinct populations in the paper and are treated as separate populations for the purpose of the analysis. Only significant values are shown in the table. (a) indicates data presented in abstract form only.

F6-151

Race not specified.

F6-152

Hispanic and/or Mexican American.

F6-153

Comparison of data presented in Table 1 with the sum of the published studies.

F6-155

Ethnically diverse.

F6-154

When the Hispanic population reported by Hessner35 is excluded from the analysis, there is no significant difference (NA1/NA1, 35 [12%]; NA1/NA2, 143 [49%]; NA2/NA2, 115 [39%]; χ2 = 1.02, P = .60 v CA in Table 1).

In comparison to the published literature on FcγRIIa variant genotypes, there are few studies with small sample sizes reporting the frequency of variant genotypes of FcγRIIIa and FcγRIIIb in CA and FcγRIIIb in AA.23,24,32,35,61,62 Comparison of our results for FcγRIIIa in CA to those of the published literature indicates a difference for the FF genotype only.23Similarly, the distribution of the NA1/NA2 and NA2/NA2 genotypes in AA differed from the one study in the literature.35Previously, there were no published data available for FcγRIIIa in AA.

In Table 7, we present an analysis of published studies comparing the distribution of low-affinity FcγR genotypes in cohorts with a well-defined disease versus healthy controls. These studies describe the possible contribution of FcγR variants to development of the underlying disease listed in the left-hand column (Table 7). We analyzed the data presented as raw numbers in each report and reported the findings without correction. The data presented in Table 7 indicate that, in patients with systemic lupus erythematosus (SLE), the association with FcγRIIa variant genotypes varied in different populations. For example, in AA, 2 of 3 studies demonstrated an association, whereas none of the studies in CA are compelling.38,58 In the meta-analysis, the overall effect appears to be stronger for AA compared with CA (P = .001 v P = .078). On the other hand, the association between FcγRIIIa variants and SLE has been well demonstrated in both reported studies (P = .004 andP = .0072).23,24 

Table 7.

Published Studies Comparing the Distribution of Low-Affinity FcγR Genotypes in Disease Versus Normal Control Populations

FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  .066  .57 .062  22  36  11  18  50  27  Netherlands/CA Duits49 
SLE  .91  .87 .67  57  120  82  46  97  72  UK/CA Botto38 
SLE  .16  .12 .72  53  84  50  40  37  31  Germany/CA Manger40 
SLE  .61  .32 .69  12  38  16  10  49  22  Greece/CA Smyth50 
SLE  .30  .61 .12  20  24  8  14  16  12  USA/CA Smyth50 
SLE  .48  .50 .24  24  44  19  16  33  21  Netherland-USA/CA Koene61 
SLE  .13  .062f .34  11  30  15  5  38  23  USA/CA  Salmon (a)53 
SLE  .23  .086 .68  17  35  25  8  37  25  Caribbean/AA Botto38 
SLE  .015  .0065f .26  14  15  10  4  23  16  USA/AA Salmon58 
SLE  .021  .047 .011  27  50  23  37  97  80  USA/AA Salmon58 
SLE  .61  .33 1.00f  24  20  5  18  23  5  China/PR Botto38 
SLE  .0041  .0009 .41f  22  37  5  8  56  9  Korea/PR Song60 
Subtotal:  .078  .14  199 376  201  149  320  208  CA  
SLE  .085  
 .001  .0007  58  100  58  49 157  121  AA  
  .014  
 .008  .0019 46  57  10  26  79  14  PR  
  .47 
 <.0001  <.0001  303  533  269  224  556 343  Total  
  .0022         
HIT  .044  .015 .15  19  49  32  33  41  22  USA/ED Brandt45 
HIT  .022  .39f .0098f  2  13  7  4  15  0  Australia/CA Burgess57 
HIT  .065  .022 .19  61  124  79  30  35  19  Canada/ED Denomme47 
HIT  .20  .18f .79f  75  99  44  5  16  4  France/CA Bachelot-Loza39 
HIT  .90  1.00f 1.00f  20  56  26  2  8  3  USA/CA Arepally44 
HIT  .0008  .0003 .019  182  300  125  77  207  105  Germany/CA Carlsson66 
Subtotal:  .31  .13  359 641  313  151  322  153  Total  
HIT  .82          
ITP, refractory .009  .16f .0028  15  35  11  3  12  14  Ireland/CA Williams51 
ITP  .50  .31 .44f  26  52  22  10  14  4  Canada/ED Horsewood (a)46 
Subtotal:  .23  .69 41  87  33  13  26  18  Total  
ITP  .089         
 
Thrombosis anticardiolipin antibody  ND  .053 ND  25  78RR+HR 18 27RR+HR USA/CA  Salmon (a)63 
Antiphospholipid syndrome  .79  .94 .50  9  22  9  21  48  27  UK/CA  Caliz (a)55 
Wegener's granulomatosis  .47  .22 .71  38  79  32  47  71  29  USA/CA Edberg41 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  .066  .57 .062  22  36  11  18  50  27  Netherlands/CA Duits49 
SLE  .91  .87 .67  57  120  82  46  97  72  UK/CA Botto38 
SLE  .16  .12 .72  53  84  50  40  37  31  Germany/CA Manger40 
SLE  .61  .32 .69  12  38  16  10  49  22  Greece/CA Smyth50 
SLE  .30  .61 .12  20  24  8  14  16  12  USA/CA Smyth50 
SLE  .48  .50 .24  24  44  19  16  33  21  Netherland-USA/CA Koene61 
SLE  .13  .062f .34  11  30  15  5  38  23  USA/CA  Salmon (a)53 
SLE  .23  .086 .68  17  35  25  8  37  25  Caribbean/AA Botto38 
SLE  .015  .0065f .26  14  15  10  4  23  16  USA/AA Salmon58 
SLE  .021  .047 .011  27  50  23  37  97  80  USA/AA Salmon58 
SLE  .61  .33 1.00f  24  20  5  18  23  5  China/PR Botto38 
SLE  .0041  .0009 .41f  22  37  5  8  56  9  Korea/PR Song60 
Subtotal:  .078  .14  199 376  201  149  320  208  CA  
SLE  .085  
 .001  .0007  58  100  58  49 157  121  AA  
  .014  
 .008  .0019 46  57  10  26  79  14  PR  
  .47 
 <.0001  <.0001  303  533  269  224  556 343  Total  
  .0022         
HIT  .044  .015 .15  19  49  32  33  41  22  USA/ED Brandt45 
HIT  .022  .39f .0098f  2  13  7  4  15  0  Australia/CA Burgess57 
HIT  .065  .022 .19  61  124  79  30  35  19  Canada/ED Denomme47 
HIT  .20  .18f .79f  75  99  44  5  16  4  France/CA Bachelot-Loza39 
HIT  .90  1.00f 1.00f  20  56  26  2  8  3  USA/CA Arepally44 
HIT  .0008  .0003 .019  182  300  125  77  207  105  Germany/CA Carlsson66 
Subtotal:  .31  .13  359 641  313  151  322  153  Total  
HIT  .82          
ITP, refractory .009  .16f .0028  15  35  11  3  12  14  Ireland/CA Williams51 
ITP  .50  .31 .44f  26  52  22  10  14  4  Canada/ED Horsewood (a)46 
Subtotal:  .23  .69 41  87  33  13  26  18  Total  
ITP  .089         
 
Thrombosis anticardiolipin antibody  ND  .053 ND  25  78RR+HR 18 27RR+HR USA/CA  Salmon (a)63 
Antiphospholipid syndrome  .79  .94 .50  9  22  9  21  48  27  UK/CA  Caliz (a)55 
Wegener's granulomatosis  .47  .22 .71  38  79  32  47  71  29  USA/CA Edberg41 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
Myasthenia gravis  .12  .13 .054  9  18  22  10  13  7  Norway/CA Raknes32 
Periodontitis  .71  .56 .53f  63  38  4  56  38  6  Japan/PR Kobayashi31 
Meningococcal disease  .058 .81 .021  307-150 587-150 197-150 26  41  31 Russia/CA  Platonov64 
Meningococcal disease, Age >5  .022  .32 .0056  307-150 587-150 197-150 11  22  20 Russia/CA  Platonov64 
Sickle cell + S pneumoniae, .41  .22 .87  77-150 307-150 137-150 12  25  14 USA/AA  Norris59 
Sickle cell + H influenzae, .002  .0004 .43  77-150 307-150 137-150 7  3  USA/AA  Norris59 
Recurrent bacterial respiratory infections  .067  .022 .25  36  59  28  6  27  15  Netherlands/CA Sanders42 
FcγRIIIa
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; FF, VF, VV)  Control Genotype Case Genotype Country/ Ethnic Group  Reference 
FF  VF VV  FF  VF  VV  
SLE  .004  .009 .016 .19  28  44  15  41  22  7  Netherlands/ USA/CA Koene61 
SLE  .0072  .0017 .013 .46  29  69  15  87  92  21  USA/CA Wu24 
Subtotal:  .003  <.0001  57 113  30  128  114  28  
SLE   .0015 
  .21         
FcγRIIIb
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; 1/1, 1/2, 2/2) Control Genotype Case Genotype Country/ Ethnic Group  Reference  
1/17-152 1/2  2/2  1/1 1/2  2/2  
Myasthenia gravis  .7096  .47f .54 .86  4  28  17  4  15  11  Norway/CA Raknes32 
SLE  .78  .58 .54 .82  11  39  37  11  28  31  Netherlands USA/CA Koene61 
Recurrent bacterial respiratory infections  .09027-151 .0297-151 .32 .68  None  10  19  19  Netherlands/CA Saunders42 
FcγRIIa
DiseaseAssociation by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; HH v HR + RR, RR vHR + HH, P value)Control GenotypeCase GenotypeCountry/ Ethnic Group Reference
HH HRRR HH HR RR
Myasthenia gravis  .12  .13 .054  9  18  22  10  13  7  Norway/CA Raknes32 
Periodontitis  .71  .56 .53f  63  38  4  56  38  6  Japan/PR Kobayashi31 
Meningococcal disease  .058 .81 .021  307-150 587-150 197-150 26  41  31 Russia/CA  Platonov64 
Meningococcal disease, Age >5  .022  .32 .0056  307-150 587-150 197-150 11  22  20 Russia/CA  Platonov64 
Sickle cell + S pneumoniae, .41  .22 .87  77-150 307-150 137-150 12  25  14 USA/AA  Norris59 
Sickle cell + H influenzae, .002  .0004 .43  77-150 307-150 137-150 7  3  USA/AA  Norris59 
Recurrent bacterial respiratory infections  .067  .022 .25  36  59  28  6  27  15  Netherlands/CA Sanders42 
FcγRIIIa
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; FF, VF, VV)  Control Genotype Case Genotype Country/ Ethnic Group  Reference 
FF  VF VV  FF  VF  VV  
SLE  .004  .009 .016 .19  28  44  15  41  22  7  Netherlands/ USA/CA Koene61 
SLE  .0072  .0017 .013 .46  29  69  15  87  92  21  USA/CA Wu24 
Subtotal:  .003  <.0001  57 113  30  128  114  28  
SLE   .0015 
  .21         
FcγRIIIb
 
Disease  Association by Locus Overall (3 × 2 table; P value)  Association by Genotype (2 × 2 table; P value; 1/1, 1/2, 2/2) Control Genotype Case Genotype Country/ Ethnic Group  Reference  
1/17-152 1/2  2/2  1/1 1/2  2/2  
Myasthenia gravis  .7096  .47f .54 .86  4  28  17  4  15  11  Norway/CA Raknes32 
SLE  .78  .58 .54 .82  11  39  37  11  28  31  Netherlands USA/CA Koene61 
Recurrent bacterial respiratory infections  .09027-151 .0297-151 .32 .68  None  10  19  19  Netherlands/CA Saunders42 

Table 7 includes published studies in which the raw numbers were available for recalculation. Studies listed more than once and report distinct populations in the paper are treated as separate populations for the purpose of the analysis. Analysis of individual studies and subtotals of comparable studies were analyzed by χ2 3 × 2 test (with 2 degrees of freedom) for overall significance and also by χ2 2 × 2 test (with 1 degree of freedom) for each genotype, when relevant. Raw values are presented and not corrected in the table. Thus, values may differ from the published data because of correction factors determined by the investigators. In selected studies in which there were too few measurements in a cell, the Fischer exact test was performed and is indicated by an f. The following symbols indicate ethnic background: CA, Caucasians (North American or European); AA, African Americans; PR, Pacific Rim; ED, ethnically diverse.

Abbreviations: SLE, systemic lupus erythematosus; HIT, heparin induced thrombocytopenia; ITP, idiopathic thrombocytopenia purpura.

F7-150

Indicates a control population used for multiple comparisons; however, the numbers were included only once in the sum for the meta-analysis.

F7-151

Comparison made with our Caucasian control population.

F7-152

In the table, 1 = NA1 and 2 = NA2.

Published studies exploring the association between low-affinity FcγR genotypes and phenotypic differences within a specific disease population are presented in Table 8. A meta-analysis was performed on studies examining SLE and nephritis at the FcγRIIa locus; the individual studies indicate that the overall association at this locus is weak, at best. In the absence of significance at the locus overall, it is difficult to interpret the marginal association observed between H/H genotype and nephritis in AA with SLE. Table 8 also includes single studies that associate 1 more FcγR with renal dysfunction in Wegener's granulomatosis, thymoma in myasthenia gravis, granulomas or auto-immune disease in chronic granulomatous disease, recurrence of periodontitis, hemolytic anemia in SLE, and severe meningococcal infection.31-33,40,41,64 

Table 8.

Published Studies Exploring the Association Between Low-Affinity FcγR Genotypes and Phenotype Within a Single Disease Population

FcγRIIa
Primary Disease Endpoint Association by Locus Overall (3 × 2 table; P value)Association by Genotype (2 × 2 table; HHv HR + RR, RR v HR + HH, P value)Genotype: Patients Without EndpointGenotype: Patients With EndpointCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  Nephritis  .94  .036 .20  25  49  37  12  48  43  USA/AA Salmon58 
SLE  Nephritis  .20  .077 .28  27  19  15  13  18  16  Germany/CA Manger40 
SLE  Nephritis  .29  .28f .76f  7  39  12  5  10  5  UK/CA Smyth50 
SLE  Nephritis  .51  .38 .77  9  7  7  5  9  5  Greece/CA Smyth50 
SLE  Nephritis  .074  .19 .029  11  26  8  7  24  19  Netherlands/CA Duits49 
SLE  Nephritis  .68  .38 .77  57  120  82  9  13  9  UK/CA Botto38 
SLE  Nephritis  .63 .39 1.00f  17  35  25  2  9  5  Caribbean/AA Botto38 
Subtotal:  Nephritis  .55 .69  111  211  124  39  74  54  CA 
SLE    .27  
  .57  .019  42  84 62  14  57  48  AA  
   .19  
  .07  .059  153  295  186  53  131  102 Total  
   .055         
SLE  Proteinuria  .077 .024 .21  31  21  17  9  16  14  Germany/CA Manger40 
SLE  Hemolytic anemia  .0173 .0034f .084  40  31  25  0  6  6  Germany/CA Manger40 
Wegener's granulomatosis  Renal dysfunction  .68  .38 .72  20  25  10  27  46  19  USA/CA Edberg41 
N meningitides Infection Severe disease  .020  .011 .034  18  19  10  8  22  21  Russia/CA Platonov64 
Complement deficiency  N meningitides >10 yr  .057  .046f 1.00f  8  4  2  2  9  3  Russia/CA Platonov43 
Late complement deficiency Severe N meningitides ND  .0039f ND  17  17RR+HR 14RR+HR Russia/CA Platonov43 
HIV (Children)  S pneumoniae infection  .9377  1.00f 1.00f  7* 23* 10* 1  5  USA/HI  Abadi52 
HIV  S pneumoniae infection  .78  .66f .68f  7* 23* 10* 2  4  USA/HI  Abadi52 
Myasthenia gravis Thymoma  .048  .026f 1.00f  5  12  6  5  1  1  Norway/CA Raknes32 
Periodontitis  Disease recurrence .57  .74 .59f  9  6  0  47  32  6  Japan/PR Kobayashi31 
CGD  Granuloma  .14 .049 .59  13  40  19  18  24  12  USA/ED Foster33 
CGD  Autoimmune  .029 .69f .039f  28  63  26  3  1  5  USA/ED Foster33 
HIT  Thrombosis  .036  .12 .014  13  30  25  17  28  9  Germany/ED Carlsson66 
HIT  Thrombosis .69  .68f 1.00f  2  8  3  6  11  6  USA/ED Arepally44 
FcγRIIIb
 
Primary Disease  Endpoint  Association by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; 1/1v 1/2 + 2/2, 2/2 v 1/1 + 1/2, Pvalue)  Genotype: Patients Without Endpoint  Genotype: Patients With Endpoint Country/ Ethnic Group  Reference  
1/1  1/2  2/2  1/1 1/2  2/2  
Periodontitis  Disease recurrence  .032 .0098 .29f  10  4  1  27  39  19  Japan/PR Kobayashi31 
CGD  Granuloma  .022 .0066f .65  12  30  31  1  29  26  USA/ED Foster33 
FcγRIIa
Primary Disease Endpoint Association by Locus Overall (3 × 2 table; P value)Association by Genotype (2 × 2 table; HHv HR + RR, RR v HR + HH, P value)Genotype: Patients Without EndpointGenotype: Patients With EndpointCountry/ Ethnic Group Reference
HH HRRR HH HR RR
SLE  Nephritis  .94  .036 .20  25  49  37  12  48  43  USA/AA Salmon58 
SLE  Nephritis  .20  .077 .28  27  19  15  13  18  16  Germany/CA Manger40 
SLE  Nephritis  .29  .28f .76f  7  39  12  5  10  5  UK/CA Smyth50 
SLE  Nephritis  .51  .38 .77  9  7  7  5  9  5  Greece/CA Smyth50 
SLE  Nephritis  .074  .19 .029  11  26  8  7  24  19  Netherlands/CA Duits49 
SLE  Nephritis  .68  .38 .77  57  120  82  9  13  9  UK/CA Botto38 
SLE  Nephritis  .63 .39 1.00f  17  35  25  2  9  5  Caribbean/AA Botto38 
Subtotal:  Nephritis  .55 .69  111  211  124  39  74  54  CA 
SLE    .27  
  .57  .019  42  84 62  14  57  48  AA  
   .19  
  .07  .059  153  295  186  53  131  102 Total  
   .055         
SLE  Proteinuria  .077 .024 .21  31  21  17  9  16  14  Germany/CA Manger40 
SLE  Hemolytic anemia  .0173 .0034f .084  40  31  25  0  6  6  Germany/CA Manger40 
Wegener's granulomatosis  Renal dysfunction  .68  .38 .72  20  25  10  27  46  19  USA/CA Edberg41 
N meningitides Infection Severe disease  .020  .011 .034  18  19  10  8  22  21  Russia/CA Platonov64 
Complement deficiency  N meningitides >10 yr  .057  .046f 1.00f  8  4  2  2  9  3  Russia/CA Platonov43 
Late complement deficiency Severe N meningitides ND  .0039f ND  17  17RR+HR 14RR+HR Russia/CA Platonov43 
HIV (Children)  S pneumoniae infection  .9377  1.00f 1.00f  7* 23* 10* 1  5  USA/HI  Abadi52 
HIV  S pneumoniae infection  .78  .66f .68f  7* 23* 10* 2  4  USA/HI  Abadi52 
Myasthenia gravis Thymoma  .048  .026f 1.00f  5  12  6  5  1  1  Norway/CA Raknes32 
Periodontitis  Disease recurrence .57  .74 .59f  9  6  0  47  32  6  Japan/PR Kobayashi31 
CGD  Granuloma  .14 .049 .59  13  40  19  18  24  12  USA/ED Foster33 
CGD  Autoimmune  .029 .69f .039f  28  63  26  3  1  5  USA/ED Foster33 
HIT  Thrombosis  .036  .12 .014  13  30  25  17  28  9  Germany/ED Carlsson66 
HIT  Thrombosis .69  .68f 1.00f  2  8  3  6  11  6  USA/ED Arepally44 
FcγRIIIb
 
Primary Disease  Endpoint  Association by Locus Overall (3 × 2 table; P value) Association by Genotype (2 × 2 table; 1/1v 1/2 + 2/2, 2/2 v 1/1 + 1/2, Pvalue)  Genotype: Patients Without Endpoint  Genotype: Patients With Endpoint Country/ Ethnic Group  Reference  
1/1  1/2  2/2  1/1 1/2  2/2  
Periodontitis  Disease recurrence  .032 .0098 .29f  10  4  1  27  39  19  Japan/PR Kobayashi31 
CGD  Granuloma  .022 .0066f .65  12  30  31  1  29  26  USA/ED Foster33 

Table 8 includes published studies in which the raw numbers were available for recalculation. Studies listed more than once and report distinct populations in the paper are treated as separate populations for the purpose of the analysis. Analysis of individual studies and subtotals of comparable studies were analyzed by χ2 3 × 2 test (with 2 degrees of freedom) for overall significance and also by χ2 2 × 2 test (with 1 degree of freedom) for each genotype, when relevant. Raw values are presented and not corrected in the table. Thus, values may differ from the published data because of correction factors determined by the investigators. In selected studies in which there were too few measurements in a cell, the Fischer exact test was performed and is indicated by an f. The following symbols indicate ethnic background: CA, Caucasians (European/North American background); AA, African Americans; PR, Pacific Rim; HI, Hispanic; ED, ethnically diverse.

Abbreviations: SLE, systemic lupus erythematosus; HIT, heparin induced thrombocytopenia; ITP, idiopathic thrombocytopenia purpura; HIV, human immunodeficiency virus infection; CGD, chronic granulomatous disease.

*Indicates a control population used for multiple comparisons; however, the numbers were included only once in the sum for the meta-analysis.

In this study, we analyzed the distribution of variant alleles of members of the low-affinity FcγR family, including FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIIb, and SH-FcγRIIIb, in 395 healthy, normal individuals. We present a substantially larger healthy cohort than previously published studies and specifically examined both single allelic frequencies and the possibility of nonrandom distribution of variant genotypes. Our data indicate that there is a marginal difference in the distribution of genotypes between AA and CA for the 158V/F genotype of FcγRIIIa (P = .048), whereas no difference was detected for the FcγRIIa and FcγRIIIb genotypes. Notably, our study represents the largest collection of AA controls analyzed at the FcγRIIa and FcγRIIIb loci. Furthermore, we report the first data on allelic distribution of the variant alleles V and F of FcγRIIIa in the AA population.

Despite the fact that the FcγRIIa, FcγRIIIa, and FcγRIIIb genes are most likely derived from a common ancestral gene and are clustered in close proximity on chromosome 1q22, we did not find strong evidence for nonrandom distribution of variant FcγR genotypes within our healthy, control population.4 In the course of our analysis, we only found evidence for a tendency towards a skewed distribution of combinations of the 158 F/F genotype of FcγRIIIa with FcγRIIIB genotypes. The significance of this finding will be borne out in future studies of comparable healthy control populations. The tendency towards a skewed distribution was seen only in the CA population and not in the AA population. Overall, we conclude that, in our population of healthy controls of AA and CA background, FcγR genotypes for the low-affinity receptors, FcγRIIa, FcγRIIIa, and FcγRIIIb, are randomly distributed. Although it has previously been suggested that linkage disequilibrium exists between the NA1 phenotype of FcγRIIIb and the high responder of FcγRIIa, this earlier study relied on phenotype and not genotype data.5 Because the study did not directly examine the distribution of genotypes or allelic frequencies of both genes, FcγRIIa and FcγRIIIb, it is difficult to conclude that linkage disequilibrium exists. However, genotype analysis of our control population did not confirm an association between the pairs of loci genotypes previously reported. These results provide a foundation for future association studies that will look at multiple genotypes of the low-affinity FcγR.

Recently, a new alloantigen of FcγRIIIb, named SH-FcγRIIIb, has been characterized; it differs from the FcγRIIIb-NA2 allele by a single nucleotide change (C for A at position 266) that results in the substitution of a hydrophobic alanine with an aspartic acid residue.10,11 The structural and functional implications of this change are not known. We found that the frequency of the SH variant differs between AA and CA (P < .0001); only 3.8% of CA were SH-FcγRIIIb positive, whereas 25% of AA were SH-FcγRIIIb positive. These data are in agreement with those of other reports.10,11,37 Our results confirm other studies showing that the SH-FcγRIIIb is identified in individuals in whom a fragment can be amplified with NA2-specific primers.11,37 Because there is only a single base difference between NA2 and SH-FcγRIIIb, it could be inferred that the SH-FcγRIIIb is a point-mutated allele of NA2. However, we have considered it as a separate entity for the present analysis. Furthermore, the ability to identify individuals with the NA1 allele plus an amplicon generated with NA2-specific primers that is incompletely digested with SfaN1 (ie, the sequence includes both an A and C with the former denoting the FcγRIIIB) provides evidence for duplication of the gene in selected individuals.11 Interestingly, in individuals in whom a product can be amplified with NA2-specific primers, we did not see evidence of preferential distribution of FcγRIIIb-NA2 genotype and SH-FcγRIIIb. Further studies across generations are required to sort out the exact mode of inheritance. On the other hand, in selected individuals in whom a product could be amplified with NA2-specific primers, only the SH-FcγRIIIb sequence was detected; Table 5indicates that there are 14 AA and 1 CA with only SH-FcγRIIIb sequence detected and no NA2 allele present. These individuals could have the FcγRIIIb null gene and would phenotype as NA2 but have no NA2 genotype.

The FcγRIIb has been shown to have an inhibitory effect on phagocytosis mediated by FcγRIIa and, to a lesser extent, on phagocytosis mediated by FcγRIIIa.65 Two cDNA clones that differ by a single base at nucleotide 885 have been reported for the isoform FcγRIIb1 and are thought to represent allelic variation.29 The change in an amino acid of the cytoplasmic domain (tyrosine substituted by an aspartic acid) has been reported to display differences in receptor internalization and capping.30 The failure to detect a single G at nucleotide 885 at the genomic level in 70 healthy controls indicates that, if the polymorphism exists, it is very rare. Although we cannot exclude the possibility that our amplification primers could have preferentially recognized a contiguous polymorphic region, linked to the T allele, it is unlikely, because no polymorphism was identified in this region in a previous study.29 

When we compared our data with a compilation of reported healthy controls, we uncovered a number of interesting findings. Differences in the distribution of variant alleles within healthy controls were apparent for some loci but not for others, depending on the group studied. For example, comparison of our population with 27 reported populations in Table 6 demonstrated no difference for FcγRIIa (n = 2,419 for CA and n = 227 for AA), but there was an apparent difference between our population and the reported literature at the FcγRIIIb locus (n = 392 for CA). When the Hispanic population reported by Hessner et al35 is excluded from the FcγRIIIb CA population, there is no significant difference between our population and the remaining CA populations (χ2 = 1.02, P = .60). The issue of geographic and ethnic background is critical in interpreting these studies. Differences in either of these can account for variations in distribution of variant alleles and probably reflect varying evolutionary challenges. Although we analyzed AA and CA, the published literature includes studies of populations from the Far East and Indian subcontinent. Notably, there is an apparent difference between populations from the Far East and CA at the FcγRIIa locus. Lastly, the data in Table 6 indicate that sample size can influence the distribution of variant genotypes. It is not surprising to find a difference between 1 of the smaller studies (n = 49) and the sum of 23 studies. On the other hand, 2 of the large studies of FcγRIIa differed from the sum of the remaining populations. This might reflect that there are actual differences in ethnic populations that become apparent when large enough populations are compared; in turn, these observa-tions underscore the subtle differences between populations of the same ethnic background yet different geographical location.

Recently, a number of groups have investigated the clinical significance of variant alleles in FcγRIIa, FcγIIIa, and FcγIIIb in disease populations. In Table 7, we present a compilation of reported studies and include recalculation of raw data without correction factors. Specifically, we looked at the overall locus and also an association between susceptibility to a disease and individual genotypes. Although the strength of a meta-analysis is undermined by variations in inclusion criteria and patient populations, several points emerge from the analysis. First, the association of variant alleles and disease susceptibility varies between ethnic groups. For example, the meta-analysis of SLE in Table 7 indicates that the association between SLE and FcγRIIa variants is strong in populations of AA and Pacific Rim (PR) background, whereas in CA, the association is marginal. Second, a stronger association was observed for the same disease, SLE, but at a different locus, FcγRIIIa, in CA. These data suggest that differences in the biological role of low-affinity FcγR receptors could influence disease susceptibility. Third, the importance of looking at different populations with sufficient numbers is critical for determining the validity of a proposed association. For example, the proposed association between heparin-induced thrombocytopenia and FcγRIIa variants was based on a series of studies, some of which included a small number of patients.39,44,45,47,57,66However, a meta-analysis presented in Table 7 of the combined data does not support the proposed association. Lastly, the ability to discern an association between outcomes within a population with a common disease depends on adequate patient numbers.

An analysis of published studies exploring the association between low-affinity FcγR genotypes and phenotype within a single disease population is presented in Table 8. We identified 5 papers reporting on 7 different populations examining a possible association between FcγRIIa variants and nephritis in SLE and found no evidence to support such an association.38,40,49,50,58 There are a number of promising analyses in patients with CGD, meningococcal infection, or SLE and hemolytic anemia that propose new insights into disease pathogenesis.31,33,40,43,64 Clearly, further studies are required to validate and expand the observations, but the ability to observe in vivo the effect of subtle biologic differences (as demonstrated in known variants of the FcγR) provides an important avenue of investigation. In an exploratory study, the combination of low-affinity FcγR, FcγRIIa, FcγRIIIa, and FcγRIIIb was studied in a cohort of CGD patients; coinheritance of variant FcγRIIa and FcγRIIIb genotypes was associated with a greater likelihood for developing granulomas in CGD.33 Similarly, the study also identified a possible association between variant FcγR and other molecules of innate immunity (ie, FcγRIIa and mannose-binding lectin in autoimmune complications of CGD).

In summary, we present genotype analysis of a large healthy control population at multiple loci of low-affinity FcγR and found that the 2-locus genotypes are generally randomly distributed. Accordingly, for the purpose of interpreting population studies, the distribution of variant genotypes of FcγRIIa, FcγRIIIa, and FcγRIIIb may be considered independent. These results provide a foundation for association studies that will seek to analyze multiple FcγR genotypes simultaneously.33 

Even though we did not find significant distortion of the observed frequencies of the different combinations of 2-locus genotypes from their expected values, this does not rule out disequilibrium of haplotypes. In fact, given the close proximity of the 3 loci, one would expect to find disequilibrium of haplotypes. We tested for disequilibrium among pairs of loci and for all 3 loci separately in CA and AA using the program developed by Long et al.67 In CA, there was significant disequilibrium (P < .001) between all pairs of the 3 loci. In AA, there was significant disequilibrium (P < .05) between IIa-IIIa and IIIa-IIIb, but not between IIa-IIIb. Neither population showed disequilibrium of the 3 locus haplotypes.

The authors thank Steven Stein and Renee Chen for their technical assistance and Drs David Stroncek and David Venzon for their advice and comments.

T.L. was supported by a Dr. Mildred Scheel Stipendium, Deutsche Krebshilfe e.V.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
van de Winkel
J
Capel
P
Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications.
Immunol Today
14
1993
215
2
Rascu
A
Repp
R
Westerdaal
N
Kalden
J
de Winkel
J
Clinical relevance of Fc-gamma-receptor polymorphisms.
Ann NY Acad Sci
815
1997
282
3
Gessner
JE
Heiken
H
Tamm
A
Schmidt
RE
The IgG Fc receptor family.
Ann Hematol
76
1998
231
4
Peltz
GA
Grundy
HO
Lebo
RV
Yssel
H
Barsh
GS
Moore
KW
Human Fc gamma RIII: Cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG.
Proc Natl Acad Sci USA
86
1989
1013
5
Schnackenberg
L
Flesch
BK
Neppert
J
Linkage disequilibria between Duffy blood groups, Fc gamma IIa and Fc gamma IIIb allotypes.
Exp Clin Immunogenet
14
1997
235
6
Kluck
PM
Wiegant
J
Jansen
RP
Bolk
MW
Raap
AK
Willemze
R
Landegent
JE
The human interleukin-6 receptor alpha chain gene is localized on chromosome 1 band q21.
Hum Genet
90
1993
542
7
Walsh
MT
Divane
A
Whitehead
AS
Fine mapping of the human pentraxin gene region on chromosome 1q23.
Immunogenetics
44
1996
62
8
Watson
ML
Kingsmore
SF
Johnston
GI
Siegelman
MH
Le Beau
MM
Lemons
RS
Bora
NS
Howard
TA
Weissman
IL
McEver
RP
Genomic organization of the selectin family of leukocyte adhesion molecules on human and mouse chromosome 1.
J Exp Med
172
1990
263
9
Su
Y
Brooks
DG
Li
L
Lepercq
J
Trofatter
JA
Ravetch
JV
Lebo
RV
Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients.
Proc Natl Acad Sci USA
90
1993
10856
10
Bux
J
Stein
E
Bierling
P
Fromont
P
Clay
M
Stroncek
D
Santoso
S
Characterization of a new alloantigen (SH) on the human neutrophil Fcγ-receptor IIIb.
Blood
89
1997
1027
11
Koene
HR
Kleijer
M
Roos
D
de Haas
M
Von dem Borne
AE
FcγRIIIB gene duplication: Evidence for presence and expression of three distinct FcγRIIIB genes in NA(1+,2+)SH(+) individuals.
Blood
91
1998
673
12
Wang
DG
Fan
JB
Siao
CJ
Berno
A
Young
P
Sapolsky
R
Ghandour
G
Perkins
N
Winchester
E
Spencer
J
Kruglyak
L
Stein
L
Hsie
L
Topaloglou
T
Hubbell
E
Robinson
E
Mittmann
M
Morris
MS
Shen
N
Kilburn
D
Rioux
J
Nusbaum
C
Rozen
S
Hudson
TJ
Lander
ES
Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome.
Science
280
1998
1077
13
Gorlach
A
Lee
PL
Roesler
J
Hopkins
PJ
Christensen
B
Green
ED
Chanock
SJ
Curnutte
JT
A p47-phox pseudogene carries the most common mutation causing p47-phox-deficient chronic granulomatous disease.
J Clin Invest
100
1997
1907
14
Warmerdam
PA
van de Winkel
JG
Vlug
A
Westerdaal
NA
Capel
PJ
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.
J Immunol
147
1991
1338
15
Tax
WJ
Willems
HW
Reekers
PP
Capel
PJ
Koene
RA
Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells.
Nature
304
1983
445
16
Abo
T
Tilden
AB
Balch
CM
Kumagai
K
Troup
GM
Cooper
MD
Ethnic differences in the lymphocyte proliferative response induced by a murine IgG1 antibody, Leu-4, to the T3 molecule.
J Exp Med
160
1984
303
17
Clark
MR
Clarkson
SB
Ory
PA
Stollman
N
Goldstein
IM
Molecular basis for a polymorphism involving Fc receptor II on human monocytes.
J Immunol
143
1989
1731
18
Tate
BJ
Witort
E
McKenzie
IF
Hogarth
PM
Expression of the high responder/non-responder human Fc gamma RII. Analysis by PCR and transfection into FcR-COS cells.
Immunol Cell Biol
70
1992
79
19
Parren
PW
Warmerdam
PA
Boeije
LC
Arts
J
Westerdaal
NA
Vlug
A
Capel
PJ
Aarden
LA
van de Winkel
JG
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
J Clin Invest
90
1992
1537
20
Parren
PW
Warmerdam
PA
Boeije
LC
Capel
PJ
van de Winkel
JG
Aarden
LA
Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
J Immunol
148
1992
695
21
Ory
PA
Clark
MR
Kwoh
EE
Clarkson
SB
Goldstein
IM
Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.
J Clin Invest
84
1989
1688
22
Ory
PA
Goldstein
IM
Kwoh
EE
Clarkson
SB
Characterization of polymorphic forms of Fc receptor III on human neutrophils.
J Clin Invest
83
1989
1676
23
Koene
H
Kleijer
M
Algra
J
Roos
D
von dem Borne
A
de Haas
M
Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma RIIIa-48L/R/H phenotype.
Blood
90
1997
1109
24
Wu
J
Edberg
J
Redecha
P
Bansal
V
Guyre
P
Coleman
K
Salmon
J
Kimberly
R
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.
J Clin Invest
100
1997
1059
25
de Haas
M
Koene
H
Kleijer
M
de Vries
E
Simsek
S
van Tool
M
Roos
D
von dem Borne
A
A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
J Immunol
156
1996
2948
26
Nagarajan
S
Chesla
S
Cobern
L
Anderson
P
Zhu
C
Selvaraj
P
Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms.
J Biol Chem
270
1995
26762
27
Salmon
JE
Edberg
JC
Kimberly
RP
Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities.
J Clin Invest
85
1990
1287
28
Bredius
RG
Fijen
CA
De Haas
M
Kuijper
EJ
Weening
RS
Van de Winkel
JG
Out
TA
Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.
Immunology
83
1994
624
29
Warmerdam
PA
van den Herik-Oudijk
IE
Parren
PW
Westerdaal
NA
van de Winkel
JG
Capel
PJ
Interaction of a human Fc gamma RIIb1 (CD32) isoform with murine and human IgG subclasses.
Int Immunol
5
1993
239
30
Van den Herik-Oudijk
I
Westerdaal
N
Henriquez
N
Capel
P
Van de Winkel
J
Functional analysis of human Fc-gamma-receptor II (CDII) isoforms expressed in B lymphocytes.
J Immunol
152
1994
574
31
Kobayashi
T
Westerdaal
NA
Miyazaki
A
van der Pol
WL
Suzuki
T
Yoshie
H
van de Winkel
JG
Hara
K
Relevance of immunoglobulin G Fc receptor polymorphism to recurrence of adult periodontitis in Japanese patients.
Infect Immun
65
1997
3556
32
Raknes
G
Skeie
GO
Gilhus
NE
Aadland
S
Vedeler
C
FcgammaRIIA and FcgammaRIIIB polymorphisms in myasthenia gravis.
J Neuroimmunol
81
1998
173
33
Foster
CB
Lehrnbecher
T
Mol
F
Steinberg
SM
Venzon
DJ
Walsh
TJ
Noack
D
Rae
J
Winkelstein
J
Curnutte
JT
Chanock
SJ
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.
J Clin Invest
102
1998
2146
34
Jiang
X
Arepally
G
Poncz
M
McKenzie
S
Rapid detection of the Fc gamma RIIA-H/R (131) ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED).
J Immunol Methods
199
1996
55
35
Hessner
M
Curtis
B
Endean
D
Aster
R
Determination of neutrophil antigen gene frequencies in five ethnic groups by polymerase chain reaction with sequence-specific primers.
Transfusion
36
1996
895
36
Fromont
P
Bettaieb
A
Skouri
H
Floch
C
Poulet
E
Duedari
N
Bierling
P
Frequency of the polymorphonuclear neutrophil Fc gamma receptor III deficiency in the French population and its involvement in the development of neonatal alloimmune neutropenia.
Blood
79
1992
2131
37
Hessner
MJ
Shivaram
SM
Curtis
BR
Dinauer
DM
Endean
DJ
Aster
RH
Neutrophil antigen SH gene frequencies in six racial groups, determined by allele-specific polymerase chain reaction.
Blood
92
1998
16a
(abstr, suppl 1)
38
Botto
M
Theodoridis
E
Thompson
EM
Beynon
HL
Briggs
D
Isenberg
DA
Walport
MJ
Davies
KA
Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): No association with disease.
Clin Exp Immunol
104
1996
264
39
Bachelot-Loza
C
Saffroy
R
Lasne
D
Chatellier
G
Aiach
M
Rendu
F
Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis.
Thromb Haemost
79
1998
523
40
Manger
K
Repp
R
Spriewald
BM
Rascu
A
Geiger
A
Wassmuth
R
Westerdaal
NA
Wentz
B
Manger
B
Kalden
JR
van de Winkel
JG
Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: Association with clinical symptoms.
Arthritis Rheum
41
1998
1181
41
Edberg
JC
Wainstein
E
Wu
J
Csernok
E
Sneller
MC
Hoffman
GS
Keystone
EC
Gross
WL
Kimberly
RP
Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis.
Exp Clin Immunogenet
14
1997
183
42
Sanders
LA
van de Winkel
JG
Rijkers
GT
Voorhorst-Ogink
MM
de Haas
M
Capel
PJ
Zegers
BJ
Fc gamma receptor Iia (CD32) heterogeneity in patients with recurrent bacterial respiratory infections.
J Infect Dis
170
1994
854
43
Platonov
AE
Shipulin
GA
Vershinina
IV
Dankert
J
van de Winkel
JG
Kuijper
EJ
Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease.
Clin Infect Dis
27
1998
746
44
Arepally
G
McKenzie
SE
Jiang
XM
Poncz
M
Cines
DB
Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.
Blood
89
1997
370
45
Brandt
JT
Isenhart
CE
Osborne
JM
Ahmed
A
Anderson
CL
On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia.
Thromb Haemost
74
1995
1564
46
Horsewood
P
Zyba
S
Kelton
JG
Role of the platelet FcRIIa polymorphism in idiopathic thrombocytopenia purpura (ITP).
Blood
92
1998
85b
(abstr, suppl 1)
47
Denomme
G
Warkentin
T
Horsewood
P
Sheppard
J
Warner
M
Kelton
J
Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the Fc gamma RIIa “low responder” (his131) gene in patients with heparin-induced thrombocytopenia.
J Lab Clin Med
130
1997
278
48
Joutsi
JL
Javela
K
Partanen
J
Kekomaki
R
Genetic polymorphism H131R of Fcγ receptor type IIA (FcγRIIA) in a healthy Finnish population and in patients with or without platelt-associated IgG.
Eur J Hematol
61
1998
183
49
Duits
AJ
Bootsma
H
Derksen
RH
Spronk
PE
Kater
L
Kallenberg
CG
Capel
PJ
Westerdaal
NA
Spierenburg
GT
Gmelig-Meyling
FH
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients.
Arthritis Rheum
38
1995
1832
50
Smyth
LJ
Snowden
N
Carthy
D
Papasteriades
C
Hajeer
A
Ollier
WE
Fc gamma RIIa polymorphism in systemic lupus erythematosus.
Ann Rheum Dis
56
1997
744
51
Williams
Y
Lynch
S
McCann
S
Smith
O
Feighery
C
Whelan
A
Correlation of platelet Fc gammaRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura.
Br J Haematol
101
1998
779
52
Abadi
J
Zhon
Z
Dobroszycki
J
Pirofski
L
Fc gamma RIIa polymorphism in human immunodeficiency virus-infected children with invasive pneumococcal disease.
Pediatr Res
42
1997
259
53
Salmon
JE
Ng
S
Lisse
J
Friedman
AR
Reveille
JD
Alarcon
GS
Allelic variants of FcgammaRIIA may contribute to the high prevalence of nephritis in Mexican American lupus.
Arthritis Rheum
40
1997
S60
(abstr)
54
Reilly
A
Norris
C
Surrey
S
Bruchak
F
Rappaport
E
Schwartz
E
McKenzie
S
Genetic diversity in human Fc receptor II for immunoglobulin G: Fc-gamma-receptor IIA ligand-binding polymorphism.
Clin Diagn Lab Immunol
1
1994
640
55
Caliz
AR
Atsumi
T
Khamashata
MA
Amengual
O
Hughes
GRV
No correlation between FcgammaRII HR131 polymorphism and clinical manifestations of antiphospholipid syndrome (APS).
Arthritis Rheum
40
1997
S299
(abstr)
56
Osborne
JM
Chacko
GW
Brandt
JT
Anderson
CL
Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes.
J Immunol Methods
173
1994
207
57
Burgess
J
Lindeman
R
Chesterman
C
Chong
B
Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.
Br J Haematol
91
1995
761
58
Salmon
JE
Millard
S
Schachter
LA
Arnett
FC
Ginzler
EM
Gourley
MF
Ramsey-Goldman
R
Peterson
MG
Kimberly
RP
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans.
J Clin Invest
97
1996
1348
59
Norris
CF
Surrey
S
Bunin
GR
Schwartz
E
Buchanan
GR
McKenzie
SE
Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease.
J Pediatr
128
1996
813
60
Song
YW
Han
CW
Kang
SW
Baek
HJ
Lee
EB
Shin
CH
Hahn
BH
Tsao
BP
Abnormal distribution of Fcgamma IIa polymorphisms in Korean patients with systemic lupus erythematosus.
Arthritis Rheumat
41
1998
421
61
Koene
HR
Kleijer
M
Swaak
AJ
Sullivan
KE
Bijl
M
Petri
MA
Kallenberg
CG
Roos
D
van dem Borne
AE
de Haas
M
The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus.
Arthritis Rheum
41
1998
1813
62
Wainstein
E
Edberg
J
Csernok
E
Sneller
M
Hoffman
G
Gross
W
Salmon
J
Kimberly
R
Fcgamma IIIB alleles predict renal dysfunction in Wegener's granulomatosis (WG).
Arthritis Rheum
39
1996
S210
(abstr)
63
Salmon
JE
Ng
S
Sobel
R
Simantov
R
Lo
SK
Furie
R
Kaell
A
Hamburger
MI
Silverstein
R
Sammaritano
LR
FcgammaRIIA allele which binds IgG2 (FcRIIa-H131) is increased in patients with anticardiolipin antibodies and thrombosis.
Arthritis Rheum
40
1997
S300
(abstr)
64
Platonov
AE
Kuijper
EJ
Vershinina
IV
Shipulin
GA
Westerdaal
N
Fijen
CA
van de Winkel
JG
Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals.
Clin Exp Immunol
111
1998
97
65
Hunter
S
Indik
ZK
Kim
MK
Cauley
MD
Park
JG
Schreiber
AD
Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor.
Blood
91
1998
1762
66
Carlsson
L
Santoso
S
Baurichter
G
Kroll
H
Papenberg
S
Eichler
P
Westerdaal
N
Kiefel
V
van der Winkel
J
Greinacher
A
Heparin-induced thrombocytopenia: New insights into the impact of FcγRIIa-R-H131 polymorphism.
Blood
92
1998
1526
67
Long
JC
Williams
RC
Urbanek
M
An E-M algorithm and testing strategy for multiple-locus haplotypes.
Am J Hum Genet
56
1995
799

Author notes

Address reprint requests to Stephen J. Chanock, MD, Immunocompromised Host Section, Pediatric Oncology Branch, Bldg 10, Room 13N240, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; e-mail: sc83a@nih.gov.

Sign in via your Institution